In a man with hemoglobin 16.4 g/dL, hematocrit 49%, normal platelet count, normal mean corpuscular volume, and spleen size 13.5 cm, what is the appropriate workup and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Workup and Management for Suspected Polycythemia Vera

This patient requires immediate evaluation for polycythemia vera (PV) given hemoglobin 16.4 g/dL, hematocrit 49%, and splenomegaly (13.5 cm), which meets WHO diagnostic criteria for PV in men (hemoglobin >16.5 g/dL OR hematocrit >49%). 1

Diagnostic Workup

Essential Testing Required

Obtain JAK2 mutation testing immediately - this is a major diagnostic criterion for PV and present in >95% of cases. 1

Perform bone marrow aspirate and biopsy to evaluate for:

  • Age-adjusted hypercellularity
  • Trilineage myeloproliferation with pleomorphic, mature megakaryocytes
  • Rule out progression to myelofibrosis (critical given the splenomegaly) 1, 2

Measure serum erythropoietin level - subnormal levels support PV diagnosis if JAK2 is negative (minor criterion). 1

Complete blood count with differential to assess:

  • White blood cell count (look for leukocytosis >10 × 10⁹/L)
  • Platelet count (assess for thrombocytosis >400 × 10⁹/L)
  • These parameters help determine disease burden and need for cytoreductive therapy 2

Additional Evaluation

Assess thrombotic risk factors:

  • Age (≥60 years = high risk)
  • Prior thrombosis history
  • Cardiovascular risk factors 2

Evaluate for symptoms requiring cytoreductive therapy:

  • Symptomatic splenomegaly (present with 13.5 cm spleen)
  • Pruritus, night sweats, fatigue
  • Progressive leukocytosis or thrombocytosis 2

Management Strategy

Risk Stratification Determines Treatment

Low-risk patients (age <60 years AND no prior thrombosis):

  • Phlebotomy to maintain hematocrit <45% (reduces thrombotic events)
  • Aspirin 81-100 mg daily for vascular symptoms
  • Monitor every 3-6 months for disease progression
  • Cytoreductive therapy NOT recommended as initial treatment 2

High-risk patients (age ≥60 years OR prior thrombosis):

  • Phlebotomy to maintain hematocrit <45%
  • Aspirin 81-100 mg daily
  • Initiate cytoreductive therapy with hydroxyurea OR interferons (based on age and patient-specific variables)
  • Monitor response every 3-6 months 2

Special Consideration for This Patient

The splenomegaly (13.5 cm) is concerning and requires specific attention. Even if this patient is otherwise low-risk, symptomatic or progressive splenomegaly is an indication to initiate cytoreductive therapy. 2

Before starting cytoreductive therapy, bone marrow biopsy is mandatory to rule out progression to myelofibrosis, which would completely change management. 2

If Hydroxyurea Fails or Is Intolerated

Ruxolitinib is indicated for patients with:

  • Inadequate response to hydroxyurea (defined by specific criteria including persistent need for phlebotomy, uncontrolled myeloproliferation, or failure to reduce splenomegaly by >50%)
  • Intolerance to hydroxyurea (leg ulcers, mucocutaneous manifestations, cytopenias) 2

Critical Pitfalls to Avoid

Do not dismiss this as secondary polycythemia - the splenomegaly strongly suggests a myeloproliferative neoplasm. Secondary causes (sleep apnea, smoking, COPD) do not cause splenomegaly.

Do not delay bone marrow biopsy - the enlarged spleen raises concern for possible myelofibrosis, which has different prognosis and management. 1, 2

Do not target hematocrit >45% - the CYTOPV study definitively showed increased thrombotic events with hematocrit 45-50% versus <45%. 2

Recognize masked PV exists - though this patient's hemoglobin is borderline, some patients with JAK2-positive PV present with normal hemoglobin due to blood dilution or coincidental blood loss, yet still have thrombotic complications. 3 However, this patient's values meet diagnostic criteria.

References

2
Guideline

nccn guidelines insights: myeloproliferative neoplasms, version 2.2018.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Related Questions

In a 25-year-old woman with mild leukopenia, low‑normal absolute neutrophil count, borderline low absolute lymphocyte count, and mildly elevated mean corpuscular volume, what is the differential diagnosis and what laboratory studies and management steps should be pursued?
In a 64-year-old man with hemoglobin 13.9 g/dL, mean corpuscular hemoglobin 26.9 pg, and red‑cell distribution width 16 %, what is the appropriate next diagnostic and therapeutic approach?
What is the appropriate workup and management for a 71‑year‑old woman with hypertension who presents with lower‑leg pain, a dry cough, and new‑onset anemia (hemoglobin 10.3 g/dL, hematocrit 32.2 %) with thrombocytosis (platelet count 497 ×10³/µL)?
In a 71-year-old long-term care resident with mild normocytic anemia and a slightly elevated red cell distribution width, what is the most likely cause and what laboratory workup and treatment should be pursued?
In an 18-year-old male with low mean corpuscular volume (MCV 78.4 fL), platelet count of 140 ×10⁹/L, neutrophils 71.9%, lymphocytes 14%, and total bilirubin 2.3 mg/dL, what are the next diagnostic steps?
In a 35‑year‑old Black female with microcytic anemia (mean corpuscular volume 74.3 fL, red cell distribution width 15.1 %), what does an iron level of 70 µg/dL and ferritin of 71 ng/mL indicate and what is the appropriate next diagnostic step?
What is the recommended fish‑oil (EPA/DHA) dosage for reducing elevated triglyceride levels?
What daily dose of fish oil (eicosapentaenoic acid + docosahexaenoic acid) is recommended for an adult without known cardiovascular disease seeking general cardiovascular health, and what contraindications should be considered?
How should I manage a 32-year-old male presenting with myalgias, serum albumin 5.2 g/dL, leukocytosis (WBC 12.7 ×10⁹/L), and neutrophilia (absolute neutrophil count 10,668/µL)?
Does spinal cord stimulation treat neuropathic pain?
In a 32‑year‑old man with myalgias, leukocytosis and neutrophilia, does a normal creatine kinase (CK) exclude inflammatory muscle disease, and what further evaluation should be pursued?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.